Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.
The data in the WARNINGS AND PRECAUTIONS reflect exposure to Alhemo based on pooled data from clinical trials explorer3 (phase 1b), explorer4 (phase 2), explorer5 (phase 2), explorer7 (phase 3) and explorer8 (phase 3), in which a total of 320 male patients with hemophilia A with and without inhibitors and hemophilia B with and without inhibitors received at least one dose of Alhemo as routine prophylaxis. The patients were exposed for a total of 475 exposure years. Patients with HAwI (hemophilia A with inhibitors) and HBwI (hemophilia B with inhibitors)
The data described below reflect exposure of 52 patients with HAwI and HBwI who were previously treated on-demand therapy and
who were randomized in explorer7 to arm 1 to receive on- demand treatment with bypassing agents (n = 19) or arm 2 to receive
Alhemo prophylaxis (n = 33) at the recommended dosing regimen [see Clinical Studies (14.1)]. The median duration of treatment was
31.1 weeks (range 3.9, 72.9 weeks) in arm 1 (on-demand arm) and 40.1 weeks (range 3.1, 56.3 weeks) in arm 2 (Alhemo
prophylaxis).
Serious adverse reactions were reported in 6.1% of patients who received Alhemo. These serious adverse reactions were renal infarct
and hypersensitivity reaction. Permanent discontinuation of Alhemo due to an adverse reaction occurred in 1 patient due to a renal
infarct. Dosage interruptions of Alhemo due to an adverse reaction occurred in 1 patient (3%) and was a hypersensitivity reaction. The
most common adverse reactions (≥5%) were injection site reactions and urticaria (see Table 1).
Table 1. Adverse Reactions Reported in ≥5% HAwI and HBwI Patients Randomized to Alhemo in Explorer7
Adverse Reaction | Alhemo Prophylaxis N=33 (%) | On-demand Treatment N=19 (%) |
Injection site reactions | 18% | 0% |
Urticaria | 6% | 0% |
Injection site reactions included: Injection site bruising, Injection site erythema, Injection site hematoma, Injection site hemorrhage, Injection site reaction and Injection site urticaria.
Urticaria included: Urticaria and Injection site urticaria.
Patients with HA (hemophilia A without inhibitors) and HB (hemophilia B without inhibitors)
The data described below reflect exposure of 63 patients with HA and HB who were previously treated on-demand therapy and who were randomized in explorer8 to arm 1 to receive on- demand treatment with factor product (n = 21) or arm 2 to receive Alhemo prophylaxis (n = 42) at the recommended dosing regimen [see Clinical Studies (14.2)]. The median duration of treatment was 24.1 weeks (range 23.6, 56.1 weeks) in arm 1 (on- demand arm) and 32.1 weeks (range 3.9, 33.6 weeks) in arm 2 (Alhemo prophylaxis).
The most common adverse reactions (≥5%) were injection site reactions and headache (see Table 2).
Table 2. Adverse Reactions Reported in ≥5% HA and HB Patients Randomized to Alhemo in Explorer8
Adverse Reaction | Alhemo Prophylaxis N=42 (%) | On-demand Treatment N=21 (%) |
Injection site reactions | 7% | 0% |
Headache | 7% | 0% |
Injection site reactions included: injection site reaction, injection site rash, and injection site nodule